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Abstract
Background: Hepatitis C virus (HCV) infection is a global public health issue. Adequate treatment for hepatitis C
patients is important, but anticipated side effects make patients fearful of receiving treatment. Little is known about the
experiences of hepatitis C patients who have completed treatment with pegylated interferon and ribavirin. The
purpose of this study was to explore the experiences of hepatitis C patients who had undergone therapy with
pegylated interferon and ribavirin and gain an understanding of what factors contributed to completion of treatment.
Method: This was a qualitative study with 21 adult hepatitis C patients purposively sampled from outpatient liver clinics
of a medical university hospital in Taichung City, Taiwan. Participants had completed 6–12 months of therapy with
pegylated interferon and ribavirin. Data were collected through individual, face-to-face, in-depth interviews conducted in
the participants’ homes from June–October 2013. Data were analysed using conventional content analysis.
Results: Data analysis revealed three themes that described the strategies employed to alleviate and ease symptoms and
manage the processes involved: restructuring their lifestyle, adopting a positive attitude, and seeking support.
Conclusion: Hepatitis C patients face many challenges during treatment with pegylated interferon and ribavirin. These
findings provide knowledge that can be used in designing effective programs to help other Hepatitis C patients manage
the side effects of pegylated interferon and ribavirin therapy, complete treatment and improve quality of life.
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Background
Hepatitis C virus (HCV) infection is a serious health
problem; 130–150 million people globally have chronic
hepatitis C infection [1]. The prevalence of HCV infec-
tion in most countries is 1–2 %, however in Taiwan it
has been reported to be as high as 4.4 % [2]. One reason
for the higher level of HCV infection in Taiwan may be
insufficient medical resources: failure to use disposable
medical devices, blood transfusions (blood donors were
not screened for antibody to HCV in Taiwan before
1992) and the injection of drugs using shared needles
[3]. There is no available vaccine preventing HCV infec-
tion. Among HCV-infected patients, only 20 % retain
normal liver function and most of them will face an in-
creased risk of hepatocellular carcinoma (HCC) (odds
ratio of 35) in the future [4].
Antiviral therapy can increase the cure of HCV infec-
tion [1, 5]. Consequently, adequate treatment for HCV
patients is critical. Before 2011, pegylated interferon and
ribavirin (PEG/RBV) was the standard for HCV treat-
ment. The treatment duration is 24 or 48 weeks depend-
ing upon such factors as viral genotype, baseline serum
HCV RNA level, and fibrosis score on liver biopsy [6].
During the past five years, owing to the rapid develop-
ment of new anti-HCV drugs, direct-acting antivirals
(DAAs) have been approved for HCV treatment [7, 8].
A positive sustained virologic response (SVR), which is
an undetectable HCV viral load after treatment for
6 months, defines successful therapy for HCV infection [9].
The SVR rate with PEG/RBV is approximately 70–80 % for
HCV genotypes 2/3 and 45–60 % for genotypes 1/4 [5].
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More recently, the second generation of DAAs has enabled
interferon-free therapy, which has increased the SVR rate
to more than 90 % for genotype 1 [8, 10, 11]. However, con-
cerns remain about virologic relapse after completion of
therapy and the extremely high cost of these drugs in many
countries [8, 12–14]. Therefore, PEG/RBV remains the
standard treatment for HCV in numerous countries, in-
cluding Taiwan [10].
There are adverse side effects of PEG/RBV therapy,
which impact patients on several levels. The physical
side effects (nausea, fatigue, anemia, neuropsychiatric)
are unpleasant, sometimes intolerable, and are often the
major reason for discontinuation of hepatitis C treat-
ment [15, 16]. The adverse effects have a broad impact
on patients: approximately 40 % of patients are required
to reduce the dosage, and 10–15 % choose to cease ther-
apy [11]; in addition patients experience a decreased
health-related quality of life (HRQOL) [17, 18]. There-
fore, side effects from the therapy of PEG/RBV require
close monitoring in order to reduce the possibility of
discontinuing treatment.
Most studies have focused on the physiological and psy-
chological side effects of PEG/RBV therapy and the influ-
ence on a patient’s HRQOL, but little is known about how
patients who complete treatment manage these side ef-
fects. Understanding how HCV patients successfully
complete the therapy is central to gaining information on
effective strategies for coping with the discomforts of
treatment. Many studies have explored the patient's ex-
perience of treatment for hepatitis C in Western countries
[19–22], yet few reports exist for Eastern countries. The
purpose of this study was to explore the experiences of
HCV patients in Taiwan who had completed PEG/RBV
therapy in order to obtain an understanding from a differ-
ent cultural perspective of how the treatment process was
managed. Our findings can be used to design patient edu-
cation programs to teach effective strategies for managing
the obstacles of HCV treatment and support for other
HCV patients intending to undergo such therapy in
Taiwan and other countries.
Method
Design
We used a qualitative design with individual, face-to-
face, in-depth interviews to explore the experience of
treatment for hepatitis C with PEG/RBV from the pa-
tient’s viewpoint. HCV patients who had completed
combination therapy were invited to share their experi-
ences of the treatment process.
Participants
Study participants were purposefully sampled from out-
patient liver clinics at a university hospital in Taichung
City, Taiwan. Participants were included by these criteria:
≥ 20 years, chronic HCV patients who had completed 6–
12 months (24–48 weeks) of PEG/RBV therapy, and able
to communicate in Chinese or Mandarin. Patients were
excluded if they had communication difficulties or severe
cognitive deficits. Eligible patients were approached at the
liver clinic by their hepatologist who explained the study
and introduced interested patients to the first author. The
first author explained the study purpose, the amount of
time required, the necessity to audio record the inter-
views, the strategies used to protect confidentiality and
privacy, and entitlement to withdraw from the study at
any time and to refuse to answer questions for any reason.
Participants signed a consent form prior to the interview.
The study was reviewed and approved by the Research
Ethics Committee of China Medical University & Hospital
(CMUH102-REC3-058).
Data collection
An interview guide (Table 1) was designed especially for
this study, which consisted of six open-ended questions to
assist with the interview process and allow the participants
to share their experiences in more detail. The questions
were developed in consultation with a hepatologist, and
experts in medical care. Two HCV patients who had com-
pleted treatment pre-tested the interview guide, which
was revised as a result of their opinions. The pilot inter-
views were not integrated into the analysis. Demographic
data were also collected at the interview.
Data were collected from June–October 2013 in semi-
structured interviews conducted by the first author,
trained in interviewing and with 12 years of clinical ex-
perience in medical and surgical nursing. Interviews
were scheduled at a time convenient for the participant.
Individual, face-to-face, in-depth interviews were con-
ducted in the participant’s home and lasted between 45–
120 minutes. Participants were recruited for the study
until no new codes emerged from the interviews (data
saturation) [23].
Data analysis
The audio recordings were transcribed verbatim within
48 hours of the interviews, and transcripts were analyzed
by inductive content analysis. We employed conven-
tional content analysis for our data, which is generally
Table 1 Interview guide
1. How did you know that you were infected with hepatitis C?
2. What interests or worries did you have about starting treatment?
3. What kinds of symptoms from combination therapy for hepatitis C did
you have?
4. Please describe your experience. How has combination therapy
affected your life?
5. How did you deal with the symptoms of hepatitis C with combination
therapy?
6. Please describe your experience. What was the most important factor
that supported you in facing the treatment process? Why?
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used with a study design whose aim is to describe a
phenomenon. This type of design is usually appropriate
when existing theory or research literature on a
phenomenon is limited. Analysis starts with reading all
data repeatedly to achieve immersion, and coding categor-
ies are derived directly from the text data [24]. Data were
collected simultaneously with data analysis and continued
until no new information emerged. We employed a quali-
tative and inductive coding process [25].
The narrative transcripts were analysed by multiple
readings; two authors independently read the transcripts
and developed an initial list of open codes and memos
to derive categories from raw data. All three authors
participated in peer discussions, constantly checked the
coding consistency and revised the coding rules continu-
ally until sufficient coding consistency was achieved [26].
Finally, highly related codes were integrated into cat-
egories and the same core meanings of the categories
were defined as themes. After data analysis was com-
pleted, results were translated into English.
We enhanced rigor and trustworthiness of the study
by employing the four criteria of Lincoln and Guba [27].
Credibility was established in several ways: peer debrief-
ing through discussions of general methodology, tran-
scripts and analysis with two experts in qualitative
research with 13–20 years of clinical experience; pre-
testing of the interview guide by two HCV patients who
had completed combination therapy treatment; provid-
ing a private space for the interviews (scheduled at a
time convenient for the participants); and prolonged en-
gagement was established through the physician, who
had cared for the participants for three to four years in
the clinic. To establish dependability, an audit trail of all
procedural steps and methodological decisions was main-
tained. Confirmability of the transcripts was assured by
using multiple investigators. Two of the authors reviewed
the coding data and theme labels to ensure that results
were data-driven, and then all three authors discussed any
differences until consistency was achieved. Transferability
was met through purposive sampling.
Results
Participant characteristics
Findings are based on interviews with 21 participants (13
females, 8 males) who had completed PEG/RBV therapy.
The mean duration of HCV treatment was 8.4 months
(SD = 3.1). Participants’ ages ranged from 35–83 years
(mean = 60.86; SD = 11.47); the majority had a junior high
school education or higher (48 %), were married (59 %)
and 90 % lived with their families (Table 2).
Employing proactive strategies
Patients receiving the therapy with PEG/RBV for HCV re-
ported experiencing numerous uncomfortable symptoms
during treatment. In order to manage these difficulties
they employed several strategies. At the core of all of these
strategies was a proactive approach in order to take charge
of the side effects of treatment. Analysis of the data from
the transcripts identified three themes that further de-
scribed these strategies: ‘restructuring of lifestyle’, ‘adopting
a positive attitude’ and ‘seeking support’.
Restructuring of lifestyle
To cope with and adapt to the difficulties of HCV treat-
ment participants altered their lifestyle: they changed their
diet, added physical exercise to their daily routine, modi-
fied daily habits they believed detrimental to their health
and added complementary and alternative medicine
(CAM). Participants believed a healthy lifestyle could pro-
tect liver function and prevent further liver damage.
Food plays an important role in Chinese culture and
some patients were willing to change established patterns
such as eating habits and alcohol consumption in order to
reduce the physical discomfort of treatment and improve
symptoms related to HCV. One participant stated:
I used to drink alcohol, but now I rarely drink…I
changed my eating habits. I eat eggs and beef for my
breakfast and lunch, then at dinner I try not to eat
meat to give my stomach a rest… I drink a cup of
Kucha oil in the early morning before I have eaten
anything… (P2) One participant discontinued
observing a dietary restriction to improve nutrition:
“Because of the traditional Chinese custom, I cannot
eat beef. However, in order to improve the symptoms
of anemia, I have to eat beef…” (P7)
Restructuring physical activities or learning new skills
helped to manage the discomfort. One patient stated,
“Almost three times a week, I would go to the gym to do ex-
ercise and use the sauna and spa…” (P8) One participant
learned how to self-inject, “Because I needed the injection
with interferon every week, I learned how to inject it
myself…” (P6)
Eastern medicine is readily available in Taiwan and
CAM played an important part of therapy. Participants
employed massage therapy, acupuncture, and Chinese
herbal medicine to relieve their discomfort and improve
their strength. One patient reported, “When I feel
uncomfortable, I go to see the Chinese Medicine doctor,
and I have acupuncture…And for my health, I use
Chinese herbal medicine every day.” (P5) Another used
massage therapy, saying, “I went for a Chinese massage
once a week… Massage made me relax and feel comfort-
able.” (P3) Herbal tea helped another: “I drank
Ganoderma Lucidum Tea every day; I heard Gano-
derma Lucidum has an effect on the immune system and
liver protection.” (P17)
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Adopting a positive attitude
A positive attitude helped participants manage the dis-
comforts of treatment. Rather than allow the difficulties
of treatment to weigh on their emotions, they turned
their situation into one that was constructive. Some
compared their own experiences of treatment with those
suffering from other diseases, which provided them with
confidence to confront and accept treatment. A patient
previously treated for breast cancer believed HCV treat-
ment was much easier, stating, “I had surgery and
chemotherapy for breast cancer, so I‘m not afraid of
death…Compared with my cancer experience, you will
see which is better.” (P11) Another participant focused
on diseases with worse outcomes, which bolstered confi-
dence saying, “Compared to patients with serious dis-
eases, I thought ‘I’m so lucky’…Then I wasn’t afraid to
face difficulties from the treatment process.” (P21)
A positive outlook on life allowed some participants to
confront obstacles optimistically; they believed that posi-
tive thinking was a positive force. The knowledge that
HCV was treatable was an effective incentive. One par-
ticipant expressed this by stating, “I felt strange about
hepatitis C. I thought there was no way to treat it. I felt
hopeless…Then, I learned that hepatitis C can be
treated—this good information made me hopeful about
my life…” (P2) Another said, “I thought, ‘I am still young’,
I felt confident about the future…so I received the treat-
ment.” (P13)
Seeking support
Support refers to an individual’s subjective perception of
having assistance available or being cared for. During
treatment participants sought out different forms of sup-
port: informational support, emotional support and fi-
nancial support. Participants explained that acquiring
more information about HCV allowed them to better
understand the process of treatment:
I got an information pamphlet about hepatitis C from
the hospital; it provided me with some information…I
gained more knowledge about hepatitis C, I was not
afraid of the disease and its treatment…Sometimes I
looked up information about hepatitis C on the
Internet. (P20)
Emotional support of family, doctors, nurses, and
friends encouraged participants to face the challenges of
treatment. Physical symptoms were eased by support from
a nurse and doctor: “Every time I went to the clinic, the
nurse smiled at me and encouraged me…I felt pleased…
Table 2 Participants’ characteristics (N = 21)*
Participant Education Living with family Marital status Employed Treatment duration, months
1 Junior high school Yes Divorced No 12
2 University Yes Married No 6
3 Junior high school Yes Widowed No 12
4 Junior high school Yes Married No 12
5 Primary school Yes Married No 12
6 Senior high school Yes Married No 6
7 Primary school Yes Widowed No 12
8 Primary school Yes Married Yes 6
9 University Yes Married Yes 12
10 Uneducated Yes Widowed No 6
11 Primary school Yes Widowed No 6
12 University Solitary Unmarried Yes 6
13 University Yes Married Yes 6
14 Primary school Solitary Widowed Yes 6
15 Primary school Yes Married No 12
16 Primary school Yes Married No 6
17 Uneducated Yes Married No 6
18 Primary school Yes Married No 6
19 Primary school Yes Widowed No 12
20 University Yes Married Yes 6
21 Junior high school Yes Married Yes 12
*Participants =13 females, 8 males; ages ranged from 35–83 years (mean = 60.86; SD = 11.47)
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The doctor told me ‘Go! Go!’ I thought, ‘I will fight off hepa-
titis C’ … I forgot the uncomfortable symptoms of treat-
ment.” (P6) A nursing friend was a source of information
as well as motivation: “My friend is a nurse, so she has
been a great help to me…If I have any questions, I asked
my friend or the doctor…She always encouraged me.”
(P18) A doctor and family members provided comfort to
another participant:
When I went to the clinic, the doctor was concerned
for my condition, and I felt very comfortable …My son
worked in Tainan, but he called me every day…My
three children were very concerned about me. It made
me feel warm… (P3)
One of the significant side effects of treatment for HCV
is the nausea and fatigue, which can interfere with pa-
tients’ daily self-care abilities and responsibilities. Family
members who could care for the patient and assume their
responsibilities were critical to continuing treatment. A
wife’s spouse supported her when she was unable to con-
tinue with daily activities: “I felt weak; I had no strength to
hold a glass… Fortunately, my husband took care of me…
My husband helped me do housework such as hanging the
clothes, cooking, cleaning the house…” (P4)
For those who were employed (33 %), disruption of
work required financial support. Some participants suf-
fered job loss due to frequently missing work to receive
treatment. Treatment costs and the reduction of income
were heavy financial burdens that also required family
support. One patient best described this by stating:
I was a mason. When I begin to receive the treatment;
I must request sick leave every week… Finally, I
submitted my resignation. Then, my finances became
worse. I must rely on my daughter to support the daily
living expenses. (P8)
Participants expressed gratitude for the financial support
provided by health insurance. National health insurance
was implemented in Taiwan in 1995, which alleviated
much of the financial burden of healthcare. One patient
described the importance of this support: “The cost of
treating hepatitis C is paid for by the National Health In-
surance, which lets us save the cost of more than $3000
dollars and reduces our economic burden…” (P10)
Discussion
This study highlights the experiences of 21 HCV patients
who completed treatment with PEG/RBV for hepatitis C in
Taiwan. Participants reported being worried about begin-
ning therapy; they thought it would be impossible to en-
dure and were extremely afraid. However, adopting
proactive strategies to confront the adverse effects of HCV
therapy helped them endure the 24–48 weeks of treatment.
Several approaches were utilized: restructuring of lifestyle,
adopting a positive attitude, and seeking support. To our
knowledge, this is the first time an application of these
strategies has been described for HCV patients in an
Eastern country.
The standard treatment strategy was based on the ther-
apy of PEG/RBV for HCV patients, which was the only
therapy available until 2011. The recent appearance of
DAAs has changed HCV therapy. The new treatments offer
all-oral regimens, short duration of therapy (from 6–12
weeks to 24–48 weeks), few side effects, and high cure rates
(>90 %) [28]. However, use of these new treatments is re-
stricted in many areas of Asia, because of the high cost
[29]. Although the first generation of DAAs was approved
for clinical use in 2011, data regarding the long-term viro-
logic response relative to genotype and disease status is un-
clear [29]. In addition, treatment outcomes with PEG/RBV
therapy are better in Asian than non-Asian populations
due to factors such as IL28B genotype, low body weight,
and HCV genotype misclassification [30]. Therefore, PEG/
RBV is still the main standard therapy for HCV patients in
Asian countries such as Taiwan.
An added difficulty for our participants was the signifi-
cant financial burden resulting from the high cost of
treatment. The median cost for HCV treatment with
triple therapy (first generation DAA/ PEG/RBV) has
been reported to be nearly $84,000 (US dollars) per pa-
tient in New York [31]. In Taiwan, national health insur-
ance eased some of this burden resulting from treatment
with PEG/RBV. However, because patients are cared for
by family members, there is a loss of income not only as
a result of job loss for patients, but also from a reduction
in work hours for family members, and these adverse
events added to financial worries.
Taking a proactive approach to restructuring their life-
style helped participants manage the adverse physical ef-
fects of treatment, while at the same time improving
their overall health. The most common changes were al-
tering dietary habits and increasing activity levels. The
importance of a healthy diet was emphasized, which in-
cluded vitamins and other supplements. They also
stressed the importance of a diet high in vegetables and
fruits, and avoided drinking alcohol. Consistent with our
study, Stoller et al. [32] showed that HCV patients in the
Midwestern U.S. modified diet and activity level, and
made use of CAM to manage the physical and psycho-
social consequences of HCV infection. Exercise was also
included in restructuring the participants’ lives. Con-
trolled studies evaluating the effectiveness of exercise on
reducing discomfort and improving HRQOL for HCV
patients undergoing PEG/RBV therapy are suggested.
The use of CAM is growing globally. Nearly half of
the participants (47.6 %) reported using CAM as a
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medical self-care strategy [33]. Because of cultural differ-
ences and the availability of CAM in Taiwan, partici-
pants in this study may have been more likely to use
Eastern medicine to minimize the discomfort of therapy.
This was especially true for the female participants,
which may be due findings that women are 4 times more
susceptible to decreases in hemoglobin during treatment
with PEG/RBV [34]. The participants’ experiences with
Chinese massage, acupuncture, and Chinese herbal
medicine resulted in reduced side effects and thus im-
proved their HRQOL. Chronic disease patients have
used CAM to improve symptoms and HRQOL during
and after treatment in other studies [32, 35]. Additional
research evaluating the efficacy of CAM therapies for
hepatitis C patients should be considered.
A positive attitude empowered some participants with
emotional strength and the confidence that they could
endure the arduous course of treatment. In our study,
older participants drew on experience from past ill-
nesses, the awareness that some illnesses produce even
greater discomfort and the understanding that hepatitis
C was treatable. Conversely, younger people applied a
positive approach to manage their stress.
For many participants, support was an important com-
ponent for managing treatment. Knowledge about hepa-
titis C was helpful; participants who were more highly
educated searched the Internet frequently for informa-
tion about HCV. Some of these participants suggested
that healthcare professionals could assist HCV patients
by designing a dedicated hepatitis C Website. Fraenkel
et al. [35] reported that patients valued support groups
to cope with the adverse events of treatment. Formal
support resources for patients and their families are
lacking in Taiwan. Availability of support groups and de-
velopment of a social-network Website containing hepa-
titis C information would allow patients and their
families in the same situation to share their experiences.
One significant difference between hepatitis C patients
in our study and those in Western cultures is most partici-
pants (90 %) lived with their families; families were the
most common sources of support. A multitude of physical
and emotional side effects occurred during therapy; partic-
ipants’ roles shifted from independence to dependence
and normal daily routines became burdensome, which
also affected their job. Family members were an important
source of physical, psychosocial, and financial support,
which is consistent with findings reported by Fraenkel et
al. [35]. Family members are often the primary caregivers
of hepatitis C patients in Taiwan, therefore it is important
that appropriate and adequate information about hepatitis
C be made available to the family.
This study provides new insight into treatment experi-
ences of patients with CHC in Taiwan who completed
PEG/RBV therapy. Knowledge regarding these participants’
experiences could help other HCV-infected patients take a
proactive approach to develop effective strategies for deal-
ing with the many side effects, aid in preparedness for ther-
apy and improve chances for completing treatment.
Limitations
Despite its contributions, there were two limitations to
this study. First, we recruited only participants who had
completed PEG/RBV therapy (to increase homogeneity),
which may have contributed to their unique perspectives.
Future studies might consider including patients who had
discontinued HCV treatment, since such patients can aug-
ment these findings by understanding what prevented pa-
tients from completing treatment. Second, this study only
interviewed patients; data could be enriched and strength-
ened with multiple data resources. Because patients’ family
members and healthcare providers played an important
supportive role during treatment, they could offer add-
itional insight regarding the process of treatment. There-
fore, future studies might consider enrolling these support
members to enrich the data.
Conclusion
Treatment of chronic hepatitis C is a challenging process;
it is known to produce significant physiological and psy-
chological side effects, in addition to financial strains. The
participants in our study shared the strategies they
employed to manage these adversities during treatment.
Knowledge gained from their experiences can offer health-
care providers insights concerning effective management
skills that can help other HCV patients complete PEG/
RBV therapy. A patient-centered care approach is import-
ant for providing support to this unique patient popula-
tion. Therefore, we recommend that healthcare providers
build a patient-centered care model through multidiscip-
linary cooperation (hepatologist, psychiatrist, nurse, social
worker, dietician, etc.) to provide care and support for
HCV patients during the treatment period.
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